Category

News

Learning Collaborative Group Shot

RSO Hosts Learning Collaborative for Rett Clinics

Tuesday, June 4, 2019

Rettsyndrome.org hosted a clinical Learning Collaborative on May 8 and 9 in Denver. The Learning Collaborative is made up of physicians and clinicians from Rett clinics around the country who volunteered their time to share ideas in the spirit of advancing care for Rett families, and to create a universal standard of excellence across all … Read More

Dr. Horrigan

Rettsyndrome.org Appoints Joseph Horrigan, MD to Board of Directors

Friday, May 3, 2019

Rettsyndrome.org Appoints Joseph Horrigan, MD to Board of Directors CINCINNATI, OH – May 3 – Rettsyndrome.org is pleased to announce that Joseph P. Horrigan, MD has joined its Board of Directors. Dr. Horrigan’s appointment follows the excitement of several research and clinical trial advancements supported or developed through Rettsyndrome.org. Dr. Horrigan is a pediatric neuropsychiatrist … Read More

Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome Published in Neurology

Wednesday, March 27, 2019

Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome Published in Neurology, the Medical Journal of the American Academy of Neurology — Statistically Significant Improvement Indicates Trofinetide’s Potential for Treating Rett Syndrome — Trofinetide for Rett Syndrome has Fast Track Status and Orphan Drug Designation in the U.S. and Orphan Drug Designation in … Read More

Dr. Steven Kaminsky

Dr. Steven Kaminsky Retiring, RSO Honors Chief Science Officer

Thursday, March 7, 2019

Dr. Steven Kaminsky Retiring, RSO Honors Chief Science Officer Chief Science Officer Dr. Steven Kaminsky has announced his retirement this spring. Steve has served faithfully for the last seven years advancing research toward the treatment and cure of Rett syndrome. Instrumental in connecting trofinetide – a compound developed under the Department of Defense to treat … Read More